OKYO Pharma
OKYO
19 hedge funds and large institutions have $9.74M invested in OKYO Pharma in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
58% more funds holding
Funds holding: 12 → 19 (+7)
0.26% more ownership
Funds ownership: 15.76% → 16.01% (+0.26%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $10.3M → $9.74M (-$547K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$601K |
| 2 |
CL
Choreo LLC
Rockford,
Illinois
|
+$53.3K |
| 3 |
QCM
Quantinno Capital Management
New York
|
+$53.3K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$20.8K |
| 5 |
Renaissance Technologies
New York
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$587K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7.61K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.73K |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$6.15K |
OKYO Hedge Fund Activity: Q2 2026 in Review
19 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2026, worth a combined $9.74M — down 5.3% from $10.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OKYO positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $601K. The largest seller was Maven Securities, cutting an estimated $587K.
- 19 institutional investors held OKYO Pharma (OKYO) as of Q2 2026, up from 12 in Q1 2026.
- Funds reported $9.74M of OKYO Pharma stock for Q2 2026, down 5.3% quarter-over-quarter.
- 8 funds opened new OKYO Pharma positions in Q2 2026 and 1 closed out, a net change of +7 holders.
- The largest OKYO Pharma buyer in Q2 2026 was Opaleye Management, an estimated $601K added.
- The largest OKYO Pharma seller in Q2 2026 was Maven Securities, an estimated $587K sold.
Based on aggregated 13F filings for Q2 2026.